| Cash Flow | 2026-03-31 | 2025-12-31 |
|---|---|---|
| Revenue | 2,947 | 15,230 |
| Cost of revenue | 1,718 | 5,659 |
| Sales and marketing | 1,304 | 10,804 |
| Research and development-Clinical Trials And Medical Affairs | 343 | 3,020 |
| Research and development-Product Development | 205 | 1,848 |
| Research and development-Digital | 98 | 969 |
| Research and development-Quality And Regulatory | 266 | 1,733 |
| General and administrative | 2,744 | 21,353 |
| Other segment items | -2,364 | 1,401 |
| Net loss | -6,095 | -28,755 |
| Non-cash lease expense | 119 | 679 |
| Depreciation and amortization | 171 | 983 |
| Stock-based compensation | 638 | 3,146 |
| Provision for uncollectible accounts | - | 2,847 |
| Unrealized exchange gain (loss) and other | - | 206 |
| Unrealized exchange (gain) loss | -90 | - |
| Provision for inventory | 433 | 1,216 |
| Change in fair value of warrant liabilities | -4,324 | -12,800 |
| Warrant inducement expense | 4,145 | - |
| Change in fair value of debt | 750 | 3,615 |
| Change in fair value of revenue interest financing and pipe conversion option | - | -9,090 |
| Change in fair value of earn-out liabilities | - | 1,059 |
| Change in fair value of revenue interest financing | -1,820 | - |
| Change in fair value of share obligation | -120 | 370 |
| Interest paid on debt recorded at fair value | - | 2,410 |
| Loss on extinguishment of debt | - | -660 |
| Issuance costs associated with warrants recorded at fair value | 222 | 1,502 |
| Accounts receivable | -365 | -844 |
| Inventory | -176 | 486 |
| Prepaid expenses, other current and long-term assets | -172 | -800 |
| Lease liabilities | -73 | -796 |
| Accounts payable | -347 | -3,141 |
| Accrued expenses and other current liabilities | -1,363 | -5,045 |
| Net cash used in operating activities | -3,221 | -28,946 |
| Proceeds from private offerings, net of issuance costs | - | 4,597 |
| Proceeds from public offerings, net of issuance costs | - | 13,578 |
| Proceeds from equity line financing | - | 795 |
| Proceeds from warrant inducement, net of issuance costs | 2,866 | - |
| Net cash provided by financing activities | 2,866 | 18,970 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | -355 | -9,976 |
| Cash and cash equivalents and restricted cash at beginning of period | 5,742 | 15,718 |
| Cash and cash equivalents and restricted cash at end of period | 5,387 | 5,742 |
ALLURION TECHNOLOGIES, INC. (ALURW)
ALLURION TECHNOLOGIES, INC. (ALURW)